研究者
J-GLOBAL ID：201601010729843198
更新日: 2024年09月24日
小貫 律子
オヌキリツコ | Onuki Ritsuko
所属機関・部署：
研究分野 (2件)：
システムゲノム科学
, 統計科学
研究キーワード (1件)：
バイオインフォマティクス
論文 (11件)：
-
Ryu Okada, Hisanori Takenobu, Shunpei Satoh, Ryuichi P. Sugino, Ritsuko Onuki, Masayuki Haruta, Kyosuke Mukae, Atsuko Nakazawa, Jesmin Akter, Miki Ohira, et al. L3MBTL2 maintains MYCN-amplified neuroblastoma cell proliferation through silencing NRIP3 and BRME1 genes. Genes to Cells. 2024
-
HIROTAKA FUCHIZAWA, KIYOHIRO ANDO, NORIKO MOTOI, TOSHIHIKO IIZUKA, MASAHARU INOUE, KOUKI MITANI, YUTA SANO, HISANORI TAKENOBU, MASAYUKI HARUTA, RITSUKO ONUKI, et al. STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-γ-induced Apoptosis in Urothelial Cancer. Anticancer Research. 2024. 44. 5. 1925-1930
-
Kiyohiro Ando, Ryo Kurashina, Noriko Motoi, Toshihiko Iizuka, Masaharu Inoue, Riko Maruyama, Kouki Mitani, Hisanori Takenobu, Masayuki Haruta, Ritsuko Onuki, et al. Positive regulatory loop of platelet-derived growth factor DD-induced STAT3 activation is associated with poor prognosis in advanced urothelial carcinoma. Biochemical and Biophysical Research Communications. 2023. 676. 165-170
-
RYO KURASHINA, KIYOHIRO ANDO, MASAHARU INOUE, RIKO MARUYAMA, KOUKI MITANI, HISANORI TAKENOBU, MASAYUKI HARUTA, RITSUKO ONUKI, YOH MATSUOKA, TAKEHIKO KAMIJO, et al. Pretreatment Hemoglobin Levels and Platelet-to-Lymphocyte Ratio Predict Survival Benefit from Pembrolizumab in Advanced Urothelial Carcinoma. Cancer Diagnosis & Prognosis. 2023. 3. 2. 230-235
-
Motoo Nagane, Koichi Ichimura, Ritsuko Onuki, Daichi Narushima, Mai Honda-Kitahara, Kaishi Satomi, Arata Tomiyama, Yasuhito Arai, Tatsuhiro Shibata, Yoshitaka Narita, et al. Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study. Cancers. 2022. 14. 5522
もっと見る
MISC (2件)：
-
Tomoyuki Nakano, Yuko Matsushita, Ritsuko Onuki, Daisuke Shiokawa, Kiyomi Imamura, Terumi Horiuchi, Eita Uchida, Yui Kimura, Satoshi Ihara, Tomonari Suzuki, et al. DISSECTING INTRATUMORAL HETEROGENEITY OF CENTRAL NERVOUS SYSTEM GERM CELL TUMORS BY SINGLE-CELL RNA-SEQUENCING. NEURO-ONCOLOGY. 2020. 22. 340-341
-
Koichi Ichimura, Motoo Nagane, Mamoru Kato, Yoshitaka Narita, Tomokazu Aoki, Shota Tanaka, Akitake Mukasa, Toshihiko Wakabayashi, Takeo Uzuka, Hideo Nakamura, et al. BIOMARK: A PHASE II STUDY OF BEVACIZUMAB BEYOND PROGRESSION FOR NEWLY DIAGNOSED GLIOBLASTOMA: SAFETY, EFFICACY AND PROSPECTIVE BIOMARKER ANALYSIS. NEURO-ONCOLOGY. 2019. 21. 12-13
講演・口頭発表等 (10件)：
-
Development of Cancer Mutation Visualization Tools for Large Samples
(The 82nd Annual Meeting of the Japan Cancer Association 2023)
-
Informatics in Cancer Genome Research
(Informatics in Biology, Medicine and Pharmacology 2023 2023)
-
Deep Learning for mutation detection in cancer genome medicine
(The 81st Annual Meeting of the Japanese Cancer Association 2022)
-
非Germinoma中枢神経系胚細胞腫瘍の単一核遺伝子発現解析
(日本脳神経医科学会 2021)
-
中枢神経系胚細胞腫瘍の単一細胞遺伝子発現解析
(日本脳腫瘍学会プログラム・抄録集 2020)
もっと見る
学位 (1件)：
前のページに戻る
